1491 related articles for article (PubMed ID: 26775178)
41. Up-regulation of insulin-like growth factor-II receptor in reactive astrocytes in the spinal cord of amyotrophic lateral sclerosis transgenic rats.
Dagvajantsan B; Aoki M; Warita H; Suzuki N; Itoyama Y
Tohoku J Exp Med; 2008 Apr; 214(4):303-10. PubMed ID: 18441505
[TBL] [Abstract][Full Text] [Related]
42. Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis.
Mohajeri MH; Figlewicz DA; Bohn MC
Hum Gene Ther; 1999 Jul; 10(11):1853-66. PubMed ID: 10446925
[TBL] [Abstract][Full Text] [Related]
43. [Development of motor neuron restorative therapy in amyotrophic lateral sclerosis using hepatocyte growth factor].
Aoki M; Warita H; Suzuki N; Itoyama Y
Rinsho Shinkeigaku; 2009 Nov; 49(11):814-7. PubMed ID: 20030218
[TBL] [Abstract][Full Text] [Related]
44. Pharmacological inhibition of ALCAT1 mitigates amyotrophic lateral sclerosis by attenuating SOD1 protein aggregation.
Liu X; Zhang J; Li J; Song C; Shi Y
Mol Metab; 2022 Sep; 63():101536. PubMed ID: 35772643
[TBL] [Abstract][Full Text] [Related]
45. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.
Kiaei M; Petri S; Kipiani K; Gardian G; Choi DK; Chen J; Calingasan NY; Schafer P; Muller GW; Stewart C; Hensley K; Beal MF
J Neurosci; 2006 Mar; 26(9):2467-73. PubMed ID: 16510725
[TBL] [Abstract][Full Text] [Related]
46. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis.
Poon HF; Hensley K; Thongboonkerd V; Merchant ML; Lynn BC; Pierce WM; Klein JB; Calabrese V; Butterfield DA
Free Radic Biol Med; 2005 Aug; 39(4):453-62. PubMed ID: 16043017
[TBL] [Abstract][Full Text] [Related]
47. Protein disulfide isomerase ERp57 protects early muscle denervation in experimental ALS.
Rozas P; Pinto C; Martínez Traub F; Díaz R; Pérez V; Becerra D; Ojeda P; Ojeda J; Wright MT; Mella J; Plate L; Henríquez JP; Hetz C; Medinas DB
Acta Neuropathol Commun; 2021 Feb; 9(1):21. PubMed ID: 33541434
[TBL] [Abstract][Full Text] [Related]
48. A conditioning lesion provides selective protection in a rat model of Amyotrophic Lateral Sclerosis.
Franz CK; Quach ET; Krudy CA; Federici T; Kliem MA; Snyder BR; Raore B; Boulis NM
PLoS One; 2009 Oct; 4(10):e7357. PubMed ID: 19806196
[TBL] [Abstract][Full Text] [Related]
49. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS.
Hall ED; Oostveen JA; Gurney ME
Glia; 1998 Jul; 23(3):249-56. PubMed ID: 9633809
[TBL] [Abstract][Full Text] [Related]
50. Expression of a Cu,Zn superoxide dismutase typical for familial amyotrophic lateral sclerosis increases the vulnerability of neuroblastoma cells to infectious injury.
Goos M; Zech WD; Jaiswal MK; Balakrishnan S; Ebert S; Mitchell T; Carrì MT; Keller BU; Nau R
BMC Infect Dis; 2007 Nov; 7():131. PubMed ID: 17997855
[TBL] [Abstract][Full Text] [Related]
51. The human G93A-SOD1 mutation in a pre-symptomatic rat model of amyotrophic lateral sclerosis increases the vulnerability to a mild spinal cord compression.
Jokic N; Yip PK; Michael-Titus A; Priestley JV; Malaspina A
BMC Genomics; 2010 Nov; 11():633. PubMed ID: 21078175
[TBL] [Abstract][Full Text] [Related]
52. Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis.
Pollari E; Savchenko E; Jaronen M; Kanninen K; Malm T; Wojciechowski S; Ahtoniemi T; Goldsteins G; Giniatullina R; Giniatullin R; Koistinaho J; Magga J
J Neuroinflammation; 2011 Jun; 8():74. PubMed ID: 21711557
[TBL] [Abstract][Full Text] [Related]
53. Immune reactivity in a mouse model of familial ALS correlates with disease progression.
Alexianu ME; Kozovska M; Appel SH
Neurology; 2001 Oct; 57(7):1282-9. PubMed ID: 11591849
[TBL] [Abstract][Full Text] [Related]
54. Hyperactive intracellular calcium signaling associated with localized mitochondrial defects in skeletal muscle of an animal model of amyotrophic lateral sclerosis.
Zhou J; Yi J; Fu R; Liu E; Siddique T; Ríos E; Deng HX
J Biol Chem; 2010 Jan; 285(1):705-12. PubMed ID: 19889637
[TBL] [Abstract][Full Text] [Related]
55. KLF15 overexpression in myocytes fails to ameliorate ALS-related pathology or extend the lifespan of SOD1G93A mice.
Massopust R; Juros D; Shapiro D; Lopes M; Haldar SM; Taetzsch T; Valdez G
Neurobiol Dis; 2022 Jan; 162():105583. PubMed ID: 34902552
[TBL] [Abstract][Full Text] [Related]
56. How to Build and to Protect the Neuromuscular Junction: The Role of the Glial Cell Line-Derived Neurotrophic Factor.
Stanga S; Boido M; Kienlen-Campard P
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374485
[TBL] [Abstract][Full Text] [Related]
57. c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis.
Katsumata R; Ishigaki S; Katsuno M; Kawai K; Sone J; Huang Z; Adachi H; Tanaka F; Urano F; Sobue G
PLoS One; 2012; 7(9):e46185. PubMed ID: 23049975
[TBL] [Abstract][Full Text] [Related]
58. Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model.
Hayworth CR; Gonzalez-Lima F
Neuroscience; 2009 Dec; 164(3):975-85. PubMed ID: 19699279
[TBL] [Abstract][Full Text] [Related]
59. Distinct transcriptomic profile of satellite cells contributes to preservation of neuromuscular junctions in extraocular muscles of ALS mice.
Li A; Yi J; Li X; Dong L; Ostrow LW; Ma J; Zhou J
Elife; 2024 Apr; 12():. PubMed ID: 38661532
[TBL] [Abstract][Full Text] [Related]
60. Modulation of the IGF1R-MTOR pathway attenuates motor neuron toxicity of human ALS SOD1
Granatiero V; Sayles NM; Savino AM; Konrad C; Kharas MG; Kawamata H; Manfredi G
Autophagy; 2021 Dec; 17(12):4029-4042. PubMed ID: 33749521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
